Feb 12 (Reuters) - West Pharmaceutical (WST.N), opens new tab forecast annual profit above Wall Street estimates on Thursday, banking on higher demand for diabetes and obesity treatments that use its ...

Novo Nordisk CEO Mike Doustdar has a plan to steer the company through what’s been described as a “show me” year. The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Senators introduced legislation on Thursday that would ...

Throughout the year, Teva had momentum in innovative medicines, scaling its global generics and biosimilars portfolio. On the brand side, Teva said it continued to showcase strong performance of its ...

Swiss pharma giant Novartis AG NVS reported fourth-quarter core earnings per share (excluding one-time charges) of $2.03, which beat the Zacks Consensus Estimate of $1.99. The figure was also up from ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company plans to use an ...

This weight-loss leader was drubbed last year. It's a popular pick as a 2026 rebound candidate. More than that popularity, it has credible catalysts to bounce back this year. Fast-forward to 2026, and ...

Prefilled drug delivery device specialist Apiject has signed a lease for a new site in Apex, North Carolina, that will house two blow-fill-seal production lines. The 30,000-square-foot facility will ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...